Bioenvision Investors Unhappy With Genzyme Acquisition Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Web site urges shareholders to reject Genzyme’s “lowball” tender offer.
You may also be interested in...
Genzyme Next-Generation Osteoarthritis Candidate Hylastan Found Not Superior To Steroids
Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.
Genzyme Next-Generation Osteoarthritis Candidate Hylastan Found Not Superior To Steroids
Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.
Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Wirth talks about Genzyme’s contentious acquisition of AnorMED and current shareholder objections to the company’s bid to acquire clofarabine partner Bioenvision.